US FDA ‘Public Health’ Approach To Opioids May Open Up Pricing Debates

Latest effort by FDA to re-set reviews for novel opioid analgesics is off to a rocky start after three advisory committee reviews. One unintended consequences may already be apparent: by taking a broad, public health perspective on new formulations, the agency may be inviting arguments based on price.

Large US American flag on sailboat off the coast of California

The US Food & Drug Administration’s new “public health” framework for considering opioid analgesic applications made its debut in a series of advisory committee meetings in mid-January – and it did not go well for the sponsors.

Two of the three opioid formulations reviewed – Nektar Therapeutics’s new molecular entity oxycodegol and Intellipharmaceutics International Inc.’...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access